Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
40.98 (USD) • At close January 15, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities: | |||||||||||||
| Net Income
| -606.639 | -707.421 | -454.025 | -186.566 | -402.727 | -197.611 | -302.139 | -245.874 | -145.618 | -59.802 | -35.07 | -16.334 | -6.849 |
| Depreciation & Amortization
| 26.006 | 18.22 | 13.239 | 12.261 | 8.539 | 19.538 | 5.825 | 3.424 | 1.384 | 0.684 | 0.444 | 0.313 | 0.034 |
| Deferred Income Tax
| -1.619 | -1.639 | 48.669 | -169.776 | -18.939 | -167.654 | -16.246 | 6.164 | 0 | 0 | 0 | 0 | 0.013 |
| Stock Based Compensation
| 135.213 | 130.377 | 104.952 | 85.735 | 81.995 | 80.107 | 68.014 | 48.309 | 24.884 | 5.394 | 0.657 | 0.891 | 0.254 |
| Change In Working Capital
| -15.101 | 60.235 | -63.236 | 104.663 | -15.943 | -24.79 | -20.231 | 26.302 | 7.736 | 2.166 | -1.545 | 2.324 | 0.453 |
| Accounts Receivables
| -22.778 | -12.068 | -5.432 | 9.84 | -20.104 | -7.583 | -5.172 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory
| -6.93 | -9.701 | -3.117 | -1.346 | -4.451 | -5.283 | -0.757 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables
| 2.38 | 87.442 | 2.805 | 29.601 | 20.648 | 3.372 | 3.459 | 2.502 | -1.982 | 3.177 | 0.237 | 0.858 | 0.252 |
| Other Working Capital
| 12.227 | -5.438 | -57.492 | 66.568 | -12.036 | -15.296 | -23.69 | 23.8 | 9.718 | -1.011 | -1.782 | 1.466 | 0.201 |
| Other Non Cash Items
| -12.666 | 119.763 | 11.706 | 21.463 | 1.692 | -0.156 | 10.934 | 0.7 | 5.637 | 6.924 | 4.314 | 0.302 | 0.27 |
| Operating Cash Flow
| -474.806 | -380.465 | -338.695 | -132.22 | -345.383 | -290.566 | -253.843 | -160.975 | -105.977 | -44.634 | -31.2 | -12.504 | -5.825 |
| Investing Activities: | |||||||||||||
| Investments In Property Plant And Equipment
| -44.267 | -146.123 | -73.093 | -43.905 | -24.832 | -4.076 | -2.793 | -10.188 | -4.955 | -2.149 | -0.407 | -1.091 | -0.548 |
| Acquisitions Net
| 0 | -75.025 | 0 | 0 | -11.793 | 0 | -142.804 | 0 | 0 | 0 | 0 | 0 | 0 |
| Purchases Of Investments
| -526.382 | -614.735 | -1,012.187 | -850.299 | -707.163 | -509.796 | -230.487 | -442.49 | -624.226 | -208.972 | -63.953 | 0 | 0 |
| Sales Maturities Of Investments
| 746.197 | 545.075 | 890.85 | 720.638 | 718.956 | 310.219 | 431.566 | 543.795 | 338.371 | 87.974 | 16.601 | 0 | 0 |
| Other Investing Activites
| -7.548 | -0.844 | -0.942 | -5.555 | 11.793 | 170.322 | 0.934 | -1.202 | -1.541 | -0.293 | 0.025 | -0.1 | -0.376 |
| Investing Cash Flow
| 168 | -291.652 | -195.372 | -179.121 | -13.039 | -33.331 | 56.416 | 89.915 | -292.351 | -123.44 | -47.734 | -1.191 | -0.924 |
| Financing Activities: | |||||||||||||
| Debt Repayment
| 0 | 0 | 0 | 0 | 0 | 0 | -4.944 | 0 | 0 | 0 | 0 | 0.1 | 2.45 |
| Common Stock Issued
| 379.755 | 10.813 | 78.943 | 511.215 | 355.243 | 309.025 | 131.96 | 79.486 | 467.573 | 189.317 | 0.171 | 0.131 | 0 |
| Common Stock Repurchased
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.346 | 0 | 0 | 0 |
| Other Financing Activities
| 8.387 | 501.208 | 39.609 | 89.057 | 324.063 | 27.828 | 9.251 | 59.19 | 6.437 | 0.736 | 0 | 89.009 | 14.879 |
| Financing Cash Flow
| 388.142 | 501.208 | 118.552 | 600.272 | 679.306 | 336.853 | 136.267 | 138.676 | 467.573 | 184.971 | 0.171 | 89.24 | 17.329 |
| Other Information: | |||||||||||||
| Effect Of Forex Changes On Cash
| 0.462 | -1.075 | -1.194 | 1.119 | -0.165 | -0.472 | 0.528 | -0.065 | 0 | 0 | 0 | 0 | 0 |
| Net Change In Cash
| 81.798 | -171.984 | -416.709 | 290.05 | 320.719 | 12.484 | -60.632 | 67.551 | 69.245 | 16.897 | -78.763 | 75.545 | 10.58 |
| Cash At End Of Period
| 219.399 | 137.601 | 309.585 | 726.294 | 436.244 | 115.525 | 100.488 | 161.12 | 93.569 | 24.324 | 7.427 | 86.19 | 10.645 |